Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ALL: early-phase trial registry
8 of 14 indexed ALL trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 8 currently recruiting · #1,230 of 28,707 conditions by registered trial count
ALL: 14 US clinical trials tracked, 8 recruiting.
ALL is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition all
OPEN 8 | RECR 57% | LATE 0 | EARLY 8 | RANK #1230 | SPON 2
Volume-matched condition peers
Nearest open-share peer: ACL (57% recruiting · 7 trials)
ALL lists 8 open slots (57% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ALL on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ALL is recruiting above its size-band peers.
8 of 14 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of ALL trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 2 of 14 trials (14.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most ALL trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 14 trials that report a genuine target (sentinel values excluded). 10 of those (71.4%) plan for fewer than 100 participants.
-
ALL research is mostly interventional.
10 interventional and 4 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
A Long Term Follow-up Study of TScan TCR-T Products
TScan Therapeutics
NCT06976736
Amish/Mennonite Research Contact Registry
University of Pittsburgh
NCT02990572
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT03739502
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06047886
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT04644016
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago
NCT03571321
Project Baseline Health Study
Baseline Study
NCT03154346
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT05550948
Venetoclax Plus Inotuzumab for B-ALL
Dana-Farber Cancer Institute
NCT05016947
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02315612
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL
Ann & Robert H Lurie Children's Hospital of Chicago
NCT02133599
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on ALL records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ALL trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ALL page
14 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 ALL trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most ALL trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ALL condition card totals 14 registered trials; most-linked intervention Cytarabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.